… expression and site of SMARCA4 mutations, we describe two … -mutant tumors and the class
of mutations associated with … KEAP1, STK11, and KRAS mutations in patient with NSCLC, …

… KRAS mutants are thought to exist in a “constitutively” active (GTP-bound) state in cancer cells
(13). Thus, inhibition of KRAS… to KRAS G12C inhibition, were treated with inhibitors of RTK …

… On-treatment feedback reactivation of the RAS-MAPK pathway, as a result of synthesis
and GTP-loading of new KRASG12C and/or RTK-driven activation of wild-type RAS, (KRAS, …

… KRAS mutations occur in approximately one in four patients diagnosed with non-small …
KRAS G12C mutant lung cell lines. KRAS G12C inhibition in combination with the RTK inhibitors …

… of cancer with KRAS mutation; successful development of the KRAS G12C inhibitor and its
… in GTP-bound KRAS G12C activation, suppression of RTK-mediated MAPK reactivation, …

… initiation of receptor tyrosine kinase (RTK) on the cell surface … reported to be additive in
KRAS mutant tumor cell lines and … AKT inhibitor MK-2206 in KRAS mutant cancers, Citation101 …

… Signaling is initiated by the binding of a ligand to its receptor tyrosine kinase (RTK) such as
… This study revealed that while these inhibitors are developed for very specific KRAS mutants…

… of resistance to KRAS G12C inhibitors and possible … the current understanding of KRAS
mutations regarding the … to complement each other to activate RTK-RAS signaling pathways to …

… describe KRAS mutations and the biology of KRAS-mutant tumors … on KRAS inhibitors in
NSCLC patients with KRAS G12C … RTK feedback signaling in response to MEK inhibition. Upon …

… In this study, we searched for secondary KRAS mutations that would confer resistance to the
KRAS … and SHP2 inhibitor) or RTK inhibitors (cetuximab and afatinib) upstream and a MEK …